Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 2, 2015, Pages 66.e25-66.e31

  Yafi, Faysal A ^a   Brimo, Fadi ^a   Steinberg, Jordan ^a   Aprikian, Armen G ^a   Tanguay, Simon ^a   Kassouf, Wassim ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bladder cancer; Sensitivity; Specificity; Surveillance; Urinary cytology; Urinary markers

Indexed keywords

HEMOGLOBIN; NUCLEAR MATRIX PROTEIN 22; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR ANTIGEN STAT TEST; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FOLLOW UP; HEMOGLOBIN DIPSTICK TEST; HUMAN; IMMUNOCYT TEST; MAJOR CLINICAL STUDY; MALE; NUCLEAR MATRIX PROTEIN 22 BLADDERCHEK TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY; BLADDER TUMOR; CYTODIAGNOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CYTODIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 84923558821     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.06.008     Document Type: Article

References (26)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
3. Rubben H., Lutzeyer W., Fischer N., et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988, 139:283-285.
4. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 1983, 130:1083-1086.
5. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684.
6. Raitanen M.-P., Aine R., Rintala E., et al. Differences between local and review urinary cytology and diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002, 41:284-289.
7. Yafi F.A., Brimo F., Auger M., Aprikian A.G., Tanguay S., Kassouf W. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol Oncol 2013, 32:e1-e6.
8. Brimo F., Vollmer R.T., Case B., Aprikian A.G., Kassouf W., Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol 2009, 132:785-793.
9. Lopez-Beltran A., Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004, 46:170-176.
10. Bastacky S., Ibrahim S., Wilczynski S.P., et al. The accuracy of urinary cytology in daily practice. Cancer 1999, 87:118-128.
11. Budman L.I., Kassouf W., Steinberg J.R. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008, 2:212-221.
12. Vrooman O.P., Witjes J.A. Urinary markers in bladder cancer. Eur Urol 2008, 53:909-916.
13. Halling K.C., King W., Sokolova I.A., et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002, 167:2001-2006.
14. Grossfeld G.D., Carroll P.R. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am 1998, 25:661-676.
15. Kinders R., Jones T., Root R., et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998, 4:2511-2520.
16. Comploj E., Mian C., Ambrosini-Spaltro A., et al. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol 2013, 121:392-397.
17. Têtu B., Tiquert R., Harel F., Fradet Y. ImmunoCyt/uCyt+improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005, 18:83-89.
18. Carpinito G.A., Stadler W.M., Briggman J.V., et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996, 156:1280-1285.
19. Tomasini J.M., Konety B.R. Urinary markers/cytology: what and when should a urologist use. Urol Clin North Am 2013, 40:165-173.
20. Nguyen C.T., Jones J.S. Defining the role of NMP22 in bladder cancer surveillance. World J Urol 2008, 26:51-58.
21. Kamat A.M., Karam J.A., Grossman H.B., et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 2011, 108:1119-1123.
22. Horstmann M., Patschan O., Hennenlotter J., Senger E., Feil G., Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand J Urol Nephrol 2009, 43:461-466.
23. Horstmann M., Todenhöfer T., Hennenlotter J. Influence of age on false positive rates of urine-based tumor markers. World J Urol 2013, 31:935-940.
24. Todenhöfer T., Hennenlotter J., Esser M., et al. Combined application of cytology and maloecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013, 121:252-260.
25. Karaoglu I., van der Heijden A.G., Witjes J.A. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol 2013, 32(3):651-659.
26. Xylinas E., Kluth L.A., Rieken M., Lotan Y., Shariat S.F. Urine markers for detection and surveillance of bladder cancer. Urol Oncol 2014, 32(3):222-229.